Literature DB >> 11353651

In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.

K Hamamoto1, T Shimizu, N Fujimoto, Y Zhang, S Arai.   

Abstract

A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC(50) and MBC(50)) and 0.3 microg/ml (MIC(90) and MBC(90)) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11353651      PMCID： PMC90571          DOI： 10.1128/AAC.45.6.1908-1910.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect.

Authors:  F J Boswell; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.

Authors:  Y Niitu; S Hasegawa; T Suetake; H Kubota; S Komatsu; M Horikawa
Journal:  J Pediatr       Date:  1970-03       Impact factor: 4.406

3.  In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  A B Brueggemann; K C Kugler; G V Doern
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

Authors:  G H Cassell; K B Waites; M S Pate; K C Canupp; L B Duffy
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

Review 5.  Phenotypic tolerance: the search for beta-lactam antibiotics that kill nongrowing bacteria.

Authors:  E Tuomanen
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.

Authors:  Y Gohara; S Arai; A Akashi; K Kuwano; C C Tseng; S Matsubara; M Matumoto; T Furudera
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.

Authors:  S Arai; Y Gohara; A Akashi; K Kuwano; M Nishimoto; T Yano; K Oizumi; K Takeda; T Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191
  9 in total
  5 in total

1.  Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.

Authors:  Ryoichi Hamasuna; Yukio Osada; Jørgen Skov Jensen
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Mycoplasma pneumonia: Clinical features and management.

Authors:  Surender Kashyap; Malay Sarkar
Journal:  Lung India       Date:  2010-04

3.  Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

4.  In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Xue Bing; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

5.  Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.

Authors:  Karl Madaras-Kelly; Makoto Jones; Richard Remington; Christina Caplinger; Benedikt Huttner; Matthew Samore
Journal:  BMC Infect Dis       Date:  2015-04-25       Impact factor: 3.090
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.